Bessemer Group Inc. Raises Stock Holdings in Regeneron Pharmaceuticals, Inc. $REGN

Bessemer Group Inc. boosted its stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 139.1% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 2,671 shares of the biopharmaceutical company’s stock after buying an additional 1,554 shares during the quarter. Bessemer Group Inc.’s holdings in Regeneron Pharmaceuticals were worth $1,502,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also made changes to their positions in REGN. Brighton Jones LLC grew its stake in shares of Regeneron Pharmaceuticals by 261.8% in the fourth quarter. Brighton Jones LLC now owns 948 shares of the biopharmaceutical company’s stock valued at $675,000 after buying an additional 686 shares in the last quarter. Dynamic Technology Lab Private Ltd purchased a new position in Regeneron Pharmaceuticals during the 1st quarter valued at about $226,000. Ameritas Advisory Services LLC acquired a new position in Regeneron Pharmaceuticals in the 2nd quarter valued at about $45,000. Clear Creek Financial Management LLC purchased a new stake in Regeneron Pharmaceuticals during the second quarter worth about $318,000. Finally, IFP Advisors Inc lifted its position in shares of Regeneron Pharmaceuticals by 20.1% during the second quarter. IFP Advisors Inc now owns 1,230 shares of the biopharmaceutical company’s stock worth $646,000 after purchasing an additional 206 shares in the last quarter. 83.31% of the stock is owned by hedge funds and other institutional investors.

Regeneron Pharmaceuticals Stock Performance

Shares of REGN opened at $785.51 on Monday. The company has a market capitalization of $82.56 billion, a price-to-earnings ratio of 18.90, a price-to-earnings-growth ratio of 2.11 and a beta of 0.40. Regeneron Pharmaceuticals, Inc. has a 52-week low of $476.49 and a 52-week high of $821.11. The company has a quick ratio of 3.39, a current ratio of 4.13 and a debt-to-equity ratio of 0.09. The stock has a 50 day moving average price of $757.29 and a 200 day moving average price of $658.82.

Regeneron Pharmaceuticals (NASDAQ:REGN) last released its quarterly earnings data on Friday, January 30th. The biopharmaceutical company reported $11.44 earnings per share for the quarter, topping analysts’ consensus estimates of $10.74 by $0.70. Regeneron Pharmaceuticals had a net margin of 31.41% and a return on equity of 13.04%. The company had revenue of $3.88 billion for the quarter, compared to analysts’ expectations of $3.76 billion. During the same quarter last year, the company earned $12.07 earnings per share. The firm’s revenue for the quarter was up 2.5% on a year-over-year basis. Research analysts predict that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current fiscal year.

Regeneron Pharmaceuticals Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, March 5th. Shareholders of record on Friday, February 20th will be paid a $0.94 dividend. This is a boost from Regeneron Pharmaceuticals’s previous quarterly dividend of $0.88. This represents a $3.76 annualized dividend and a yield of 0.5%. The ex-dividend date is Friday, February 20th. Regeneron Pharmaceuticals’s payout ratio is currently 8.47%.

Insider Activity

In other news, Director Bonnie L. Bassler sold 1,500 shares of Regeneron Pharmaceuticals stock in a transaction dated Wednesday, January 7th. The stock was sold at an average price of $800.00, for a total transaction of $1,200,000.00. Following the sale, the director owned 1,703 shares in the company, valued at approximately $1,362,400. The trade was a 46.83% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Insiders own 7.02% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities research analysts recently weighed in on the stock. Royal Bank Of Canada upped their target price on shares of Regeneron Pharmaceuticals from $704.00 to $708.00 and gave the stock a “sector perform” rating in a research note on Wednesday, October 29th. BMO Capital Markets boosted their price target on shares of Regeneron Pharmaceuticals from $725.00 to $850.00 and gave the stock an “outperform” rating in a research note on Thursday, December 4th. Morgan Stanley increased their price objective on Regeneron Pharmaceuticals from $768.00 to $769.00 and gave the company an “equal weight” rating in a research note on Monday, February 2nd. Evercore boosted their target price on Regeneron Pharmaceuticals from $750.00 to $875.00 and gave the stock an “outperform” rating in a research note on Thursday, January 22nd. Finally, Wall Street Zen raised Regeneron Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Sunday. Three equities research analysts have rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating and eight have assigned a Hold rating to the stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $788.57.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.